Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 13-16, 2025. The company's presentation will be delivered by Ian Mortimer, President and CEO, on Monday, January 13, 2025, from 9:45-10:25 AM Pacific Time.
As a neuroscience-focused biopharmaceutical company, Xenon is dedicated to developing therapeutics for areas of high unmet medical need, particularly in epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
The presentation will be accessible via live audio webcast through the 'Investors' section of Xenon's website, with a replay available after the event. The company focuses on advancing an ion channel product portfolio, emphasizing their commitment to discovering and delivering life-changing treatments for patients.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato la sua partecipazione alla 43ª Conferenza annuale J.P. Morgan sulla salute a San Francisco, CA, programmata per il 13-16 gennaio 2025. La presentazione dell'azienda sarà effettuata da Ian Mortimer, Presidente e CEO, lunedì 13 gennaio 2025, dalle 9:45 alle 10:25 AM ora del Pacifico.
Come azienda biopharmaceutical focalizzata sulle neuroscienze, Xenon è dedicata allo sviluppo di terapie per aree di elevato bisogno medico insoddisfatto, in particolare nell'epilessia e nella depressione. Il loro prodotto di punta, azetukalner, è un apritore di canali potassici Kv7, attualmente in fase di sviluppo clinico avanzato per molteplici indicazioni.
La presentazione sarà accessibile tramite webcast audio dal vivo nella sezione 'Investitori' del sito web di Xenon, con una registrazione disponibile dopo l'evento. L'azienda si concentra sull'avanzamento di un portafoglio di prodotti per canali ionici, sottolineando il proprio impegno a scoprire e fornire trattamenti che cambiano la vita dei pazienti.
Xenon Pharmaceuticals (Nasdaq: XENE) ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan en San Francisco, CA, programada para el 13-16 de enero de 2025. La presentación de la compañía será realizada por Ian Mortimer, Presidente y CEO, el lunes 13 de enero de 2025, desde las 9:45 hasta las 10:25 AM hora del Pacífico.
Como empresa biofarmacéutica centrada en las neurociencias, Xenon está dedicada al desarrollo de terapias para áreas de alta necesidad médica no satisfecha, particularmente en epilepsia y depresión. Su producto principal, azetukalner, es un nuevo abridor de canales de potasio Kv7 que actualmente se encuentra en desarrollo clínico avanzado para múltiples indicaciones.
La presentación será accesible a través de una transmisión en vivo por audio en la sección 'Inversores' del sitio web de Xenon, con una reproducción disponible después del evento. La compañía se centra en avanzar un portafolio de productos de canales iónicos, haciendo hincapié en su compromiso de descubrir y ofrecer tratamientos que cambian la vida de los pacientes.
젠온 제약(Xenon Pharmaceuticals) (Nasdaq: XENE)는 2025년 1월 13일부터 16일까지 미국 샌프란시스코에서 열리는 제43회 JP모건 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 회사의 발표는 이안 모르티머(Ian Mortimer) 사장 겸 CEO가 2025년 1월 13일 월요일, 태평양 표준시 기준으로 오전 9시 45분부터 10시 25분까지 진행할 예정입니다.
신경과학 중심의 생명공학 회사로서 젠온은 특히 간질과 우울증과 같은 높은 의학적 필요가 있는 분야에 대한 치료제를 개발하는 데 전념하고 있습니다. 그들의 주력 제품인 아제투칼너(Azetukalner)는 현재 여러 적응증에 대해 후기 단계 임상 개발 중인 새로운 Kv7 칼륨 채널 개방제입니다.
발표는 젠온 웹사이트의 '투자자' 섹션을 통해 실시간 오디오 웹캐스트로 접근할 수 있으며, 이벤트 후에 재생이 가능합니다. 회사는 이온 채널 제품 포트폴리오를 발전시키는 데 중점을 두고 있으며, 환자에게 삶을 변화시키는 치료법을 발견하고 제공하기 위한 헌신을 강조하고 있습니다.
Xenon Pharmaceuticals (Nasdaq: XENE) a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan sur la Santé à San Francisco, CA, qui se déroulera du 13 au 16 janvier 2025. La présentation de l'entreprise sera assurée par Ian Mortimer, Président et CEO, le lundi 13 janvier 2025, de 9h45 à 10h25, heure du Pacifique.
En tant qu'entreprise biopharmaceutique axée sur les neurosciences, Xenon se consacre au développement de thérapeutiques pour des domaines de forte nécessité médicale non satisfaite, en particulier en épilepsie et en dépression. Leur produit phare, azetukalner, est un nouvel ouvreur de canaux potassiques Kv7 actuellement en développement clinique avancé pour de multiples indications.
La présentation sera accessible via un webdiffusion audio en direct dans la section 'Investisseurs' du site web de Xenon, avec une rediffusion disponible après l'événement. L'entreprise met l'accent sur l'avancement d'un portefeuille de produits à canaux ioniques, soulignant son engagement à découvrir et à fournir des traitements qui changent la vie des patients.
Xenon Pharmaceuticals (Nasdaq: XENE) hat seine Teilnahme an der 43. J.P. Morgan Healthcare Konferenz in San Francisco, Kalifornien, angekündigt, die vom 13. bis 16. Januar 2025 stattfinden soll. Die Präsentation des Unternehmens wird von Ian Mortimer, Präsident und CEO, am Montag, den 13. Januar 2025, von 9:45 bis 10:25 Uhr pazifischer Zeit gehalten.
Als biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften widmet sich Xenon der Entwicklung von Therapeutika für Bereiche mit hohem ungedecktem medizinischem Bedarf, insbesondere bei Epilepsie und Depression. Ihr führendes Produkt, azetukalner, ist ein neuartiger Kv7-Kaliumkanalöffner, der sich derzeit in der späten klinischen Entwicklung für mehrere Indikationen befindet.
Die Präsentation wird über einen Live-Audio-Webcast im Bereich 'Investoren' der Xenon-Website zugänglich sein, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist. Das Unternehmen konzentriert sich darauf, ein Produktportfolio von Ionenkanälen voranzubringen und betont sein Engagement, lebensverändernde Behandlungen für Patienten zu entdecken und bereitzustellen.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.
Company Presentation Details:
| Date: | Monday, January 13, 2025 |
| Time: | 9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time) |
| Webcast: | Register here |
| Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When is Xenon Pharmaceuticals (XENE) presenting at the 2025 J.P. Morgan Healthcare Conference?
What is azetukalner and what is its development status for XENE?
Which therapeutic areas is XENE focusing on in their drug development?
How can investors access Xenon's (XENE) J.P. Morgan Healthcare Conference presentation?
What is the main focus of Xenon's (XENE) product portfolio?
